35,998 Results

Results from a survey with patients with immune thrombocytopenia (ITP) demonstrates disease burden and impact for patients. Dova Pharma /Sobi

 Added 1 day ago

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi), presented results from an online survey highlighting...

Phase III trial of Lumoxiti shows complete response rate in hairy cell leukemia.- Innate Pharma

 Added 1 day ago

Innate Pharma shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) in relapsed or refractory...

Phase III CLL14 study of Venclexta + Gazyva shows high response rate in chronic lymphocytic leukemia.- Genentech/Roche

 Added 1 day ago

Genentech/Roche announced updated data from a pivotal Phase III CLL14 study that highlights Venclexta (venetoclax) plus Gazyva (obinutuzumab) combination treatment...

Phase III MURANO study of Venclexta plus Rituxan shows disease progression benefits in chronic lymphocytic leukemia.- Genentech/Roche

 Added 1 day ago

Genentech/Roche announced updated data from a pivotal Phase III MURANO study that highlights the impact of Venclexta (venetoclax) plus Rituxan...

Real-World data analysis of Eliquis for the treatment of venous thromboembolism in patients with active cancer.- BMS + Pfizer

 Added 1 day ago

The Bristol-Myers Squibb-Pfizer Alliance announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis...

Pooled analysis of 7.5 years data shows Imbruvica improves PFS and increases chance of complete response in mantle cell lymphoma.- AbbVie

 Added 2 days ago

AbbVie announced results of a 7.5-year pooled analysis showing earlier treatment with Imbruvica (ibrutinib) monotherapy compared to later lines of...

Phase III ELEVATE TN trial of Calquence monotherapy and combined with Gazyva shows improved PFS in chronic lymphocytic leukaemia.- AstraZeneca

 Added 2 days ago

AstraZeneca presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with...

BMS + Acceleron Pharma provide update on FDA advisory committee for Reblozyl to treat myelodysplastic syndromes.

 Added 3 days ago

Bristol-Myers Squibb Company and Acceleron Pharma Inc. announced that following the late-cycle review meeting on 4 December 2019, they were...

FDA approves Avsola, infliximab biosimilar, for all indications of the reference product.- Amgen

 Added 3 days ago

Amgen has announced that the FDA has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade (infliximab):...

Phase III trial of Instiladrin meets primary endpoint in unresponsive non-muscle invasive bladder cancer.- FerGene

 Added 3 days ago

FerGene announced positive results from the pivotal Phase III clinical trial evaluating Instiladrin (nadofaragene firadenovec) (rAd-IFN/Syn3), an investigational gene therapy,...

Load more